Literature DB >> 18341610

Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma.

I Heier1, P O Hofgaard, P Brandtzaeg, F L Jahnsen, M Karlsson.   

Abstract

Regulatory T cells (T(regs)) may inhibit immunity against cancer. Induction and expansion of T(regs) in the immunosuppressive microenvironment created by a growing tumour appear to be one of the mechanisms by which it can evade host defence. We studied the impact of CD25+ T(regs) in a B cell lymphoma model in which Rag2-/- mice received adoptive transfer of wild-type spleen cells with or without CD25+ cells, and concurrently subcutaneous inoculation of the B cell lymphoma cell line A20. We also examined the effect of engaging the glucocorticoid-induced tumour necrosis factor receptor (GITR) - an approach reported previously to abrogate the suppressive effects of T(regs). Mice that received spleen cells depleted of CD25+ T(regs) showed significantly slower tumour growth and increased survival compared with mice that received unsorted spleen cells. The T(reg)-depleted group also had significantly more CD8+ T cells infiltrating the tumours and higher levels of serum immunoglobulin G subclasses. The anti-GITR treatment had no significant effect on tumour growth, survival or immunoglobulin production. In the CD25-depleted group four of 10 mice developed clinical signs of autoimmunity, in contrast to none in the non-depleted group. Forkhead box P3+ T cells were found in tumour-draining lymph nodes in mice in the CD25-depleted group, suggesting an in vivo induction or expansion of rare transferred donor T(regs). Thus, our study showed that removal of CD25+ T(regs) enhanced anti-tumour immunity against local growth of a B cell lymphoma and that induction or expansion of T(regs) could be one mechanism by which the growing tumour evades immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18341610      PMCID: PMC2384114          DOI: 10.1111/j.1365-2249.2008.03642.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

Review 1.  Natural versus adaptive regulatory T cells.

Authors:  Jeffrey A Bluestone; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

2.  Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.

Authors:  Hiroshi Tanaka; Junta Tanaka; Jørgen Kjaergaard; Suyu Shu
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

3.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

4.  T cell homeostatic proliferation elicits effective antitumor autoimmunity.

Authors:  Wolfgang Dummer; Andreas G Niethammer; Roberto Baccala; Brian R Lawson; Norbert Wagner; Ralph A Reisfeld; Argyrios N Theofilopoulos
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

5.  Increase of regulatory T cells in the peripheral blood of cancer patients.

Authors:  Anna Maria Wolf; Dominik Wolf; Michael Steurer; Guenther Gastl; Eberhard Gunsilius; Beatrix Grubeck-Loebenstein
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

6.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.

Authors:  Fumiko Ichihara; Koji Kono; Akihiro Takahashi; Hiromichi Kawaida; Hidemitsu Sugai; Hideki Fujii
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

Review 7.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Authors:  Mitchell R Smith
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

8.  CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.

Authors:  Kutlu G Elpek; Chantale Lacelle; Narendra P Singh; Esma S Yolcu; Haval Shirwan
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

Review 9.  Foxp3 in control of the regulatory T cell lineage.

Authors:  Ye Zheng; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2007-05       Impact factor: 25.606

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  6 in total

Review 1.  Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?

Authors:  Joseph Pidala; Claudio Anasetti
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

2.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

3.  Topical treatment with black raspberry extract reduces cutaneous UVB-induced carcinogenesis and inflammation.

Authors:  F J Duncan; Jason R Martin; Brian C Wulff; Gary D Stoner; Kathleen L Tober; Tatiana M Oberyszyn; Donna F Kusewitt; Anne M Van Buskirk
Journal:  Cancer Prev Res (Phila)       Date:  2009-07

4.  Bone marrow provides an environment that prevents suppression of therapeutic graft-vs.-tumor immunity by regulatory T cells.

Authors:  Teun Guichelaar; Tuna Mutis
Journal:  Oncoimmunology       Date:  2013-04-30       Impact factor: 8.110

5.  Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody.

Authors:  Marit J van Elsas; Johan M S van der Schoot; Alexander Bartels; Kas Steuten; Duco van Dalen; Zacharias Wijfjes; Carl G Figdor; Thorbald van Hall; Sjoerd H van der Burg; Martijn Verdoes; Ferenc A Scheeren
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

6.  Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.

Authors:  Mark M Aloysius; Alastair J Mc Kechnie; Richard A Robins; Chandan Verma; Jennifer M Eremin; Farzin Farzaneh; Nagy A Habib; Joti Bhalla; Nicola R Hardwick; Sukchai Satthaporn; Thiagarajan Sreenivasan; Mohammed El-Sheemy; Oleg Eremin
Journal:  J Transl Med       Date:  2009-03-19       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.